Intellia Therapeutics (NTLA) Cash from Operations (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Cash from Operations of 117346000.0 for Q1 2026, up 21.21% year-over-year from 96814317.89 in Q1 2025, and down 69.37% quarter-over-quarter from 69285000.0 in Q4 2025.
Powered by 
Analysis
Intellia Therapeutics (NTLA) Cash from Operations (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Cash from Operations for 12 consecutive years, with 117346000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 21.21% year-over-year to 117346000.0; the TTM figure through Mar 2026 stood at 363152000.0 (up 3.71% YoY), while the FY2025 annual figure was 394736000.0, down 13.14% from the prior year.
- Cash from Operations fell to 117346000.0 in Q1 2026 per NTLA's latest filing, from 69285000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 58186000.0 in Q2 2024 and bottomed at 148930000.0 in Q1 2025.
- Historically, Cash from Operations has averaged 93431470.59 across 5 years, with a median of 89869000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Operations soared 35.58% — and 2025, when it sank 71.21%.
- Intellia Therapeutics' Cash from Operations stood at 89869000.0 in 2022, then dropped by 3.54% to 93054000.0 in 2023, then climbed by 8.45% to 85195000.0 in 2024, then increased by 18.67% to 69285000.0 in 2025, then sank by 69.37% to 117346000.0 in 2026.
- Business Quant data shows NTLA's Cash from Operations at 117346000.0 in Q1 2026, 69285000.0 in Q4 2025, and 76899000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - | -83.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -83.11 Mn |
| Mar 31, 2026 | -117.35 Mn |
| Dec 31, 2025 | -69.29 Mn |
| Sep 30, 2025 | -76.90 Mn |
| Jun 30, 2025 | -99.62 Mn |
| Mar 31, 2025 | -148.93 Mn |
| Dec 31, 2024 | -85.20 Mn |
| Sep 30, 2024 | -84.84 Mn |
| Jun 30, 2024 | -58.19 Mn |
| Mar 31, 2024 | -120.66 Mn |
| Dec 31, 2023 | -93.05 Mn |
| Sep 30, 2023 | -101.38 Mn |
| Jun 30, 2023 | -90.32 Mn |
| Mar 31, 2023 | -109.33 Mn |
| Dec 31, 2022 | -89.87 Mn |
| Sep 30, 2022 | -78.53 Mn |
| Jun 30, 2022 | -85.09 Mn |
| Mar 31, 2022 | -79.80 Mn |
| Dec 31, 2021 | -54.65 Mn |
| Sep 30, 2021 | -65.02 Mn |